TRAEs occurring with any grade incidence of ≥20% in patients treated with ibrutinib maintenance (n = 36)
| TRAE, n (%) . | All grade . | Grade 3 . | Grade 4 . |
|---|---|---|---|
| Infection | 31 (86) | 4 (11) | 1 (3) |
| Lymphocyte count decreased | 29 (80) | 12 (33) | 9 (25) |
| White blood cell decreased | 26 (72) | 7 (19) | 1 (3) |
| Diarrhea | 24 (67) | 0 | 0 |
| Platelet count decreased | 23 (64) | 0 | 0 |
| Neutrophil count decreased∗ | 21 (58) | 4 (11) | 9 (25) |
| Hypertension | 20 (56) | 8 (22) | 0 |
| Hemorrhage | 16 (44) | 2 (6) | 1 (3) |
| Skin rash | 16 (44) | 1 (3) | 0 |
| Bruising | 13 (36) | 0 | 0 |
| Myalgia | 13 (36) | 0 | 0 |
| Fatigue | 12 (33) | 2 (6) | 0 |
| Anemia | 12 (33) | 0 | 0 |
| Aspartate aminotransferase increased | 11 (31) | 1 (3) | 0 |
| Atrial fibrillation/atrial flutter | 10 (28) | 4 (11) | 0 |
| Alanine aminotransferase increased | 8 (22) | 0 | 0 |
| TRAE, n (%) . | All grade . | Grade 3 . | Grade 4 . |
|---|---|---|---|
| Infection | 31 (86) | 4 (11) | 1 (3) |
| Lymphocyte count decreased | 29 (80) | 12 (33) | 9 (25) |
| White blood cell decreased | 26 (72) | 7 (19) | 1 (3) |
| Diarrhea | 24 (67) | 0 | 0 |
| Platelet count decreased | 23 (64) | 0 | 0 |
| Neutrophil count decreased∗ | 21 (58) | 4 (11) | 9 (25) |
| Hypertension | 20 (56) | 8 (22) | 0 |
| Hemorrhage | 16 (44) | 2 (6) | 1 (3) |
| Skin rash | 16 (44) | 1 (3) | 0 |
| Bruising | 13 (36) | 0 | 0 |
| Myalgia | 13 (36) | 0 | 0 |
| Fatigue | 12 (33) | 2 (6) | 0 |
| Anemia | 12 (33) | 0 | 0 |
| Aspartate aminotransferase increased | 11 (31) | 1 (3) | 0 |
| Atrial fibrillation/atrial flutter | 10 (28) | 4 (11) | 0 |
| Alanine aminotransferase increased | 8 (22) | 0 | 0 |
Includes 1 event of febrile neutropenia.